Free Alerts   Login
Health Care › Services-Commercial Physical And Biological Research

MEDP Stock Price Correlated With Medpace Holdings Financials

MEDP Stock Price vs. Quarterly
Income Statement
Cash Flow
Balance Sheet

MEDP Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

MEDP Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

MEDP Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Vanguard Group
2,660,389 sh
-112,264 sh
Fuller & Thaler Asset Management.
939,945 sh
1,747 sh
State Street
841,192 sh
11,372 sh
Geode Capital Management
587,944 sh
2,129 sh
Boston Trust Walden Corp
562,635 sh
15,193 sh
Goldman Sachs Group
548,728 sh
162,444 sh
Riverbridge Partners
440,695 sh
-14,999 sh
American Capital Management
427,737 sh
-1,926 sh
Millennium Management
407,543 sh
-43,395 sh
Envestnet Asset Management
403,117 sh
353,955 sh
355,226 sh
1,321 sh
Price T Rowe Associates /Md/
327,011 sh
-14,710 sh
Bank Of New York Mellon
282,704 sh
-7,453 sh
Morgan Stanley
269,148 sh
76,580 sh
GW&K Investment Management
253,436 sh
-1,406 sh
Channing Capital Management
235,628 sh
-11,100 sh
Vulcan Value Partners
220,571 sh
67,229 sh
Royal Bank Of Canada
218,712 sh
-15,065 sh
Td Asset Management
204,616 sh
-31,132 sh
UBS Asset Management Americas
192,862 sh
192,862 sh
1. BASIS OF PRESENTATION Description of Business Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Share Repurchases In 2018, the Board of Directors approved a stock repurchase program which has been amended several times to increase the aggregate amount of the stock repurchase authorization. In the first quarter of 2020, the Board of Directors approved an increase in the stock repurchase authorization by $ 50.0 million. In the fourth quarter of 2020, the Board approved the stock repurchase authorization up to $ 150.0 million. In the second quarter of 2021, the Board approved an increase of $ 150.0 million to the stock repurchase program bringing the total repurchase authorization up to $ 300.0 million. For the year ended December 31, 2021, the Company repurchased 377,783 shares for $ 62.1 million. For the year ended December 31, 2020, the Company repurchased 1,183,095 shares for $ 98.3 million. As of December 31, 2021, the Company has remaining authorization of $ 190.5 million remaining under the repurchases program. As of February 10, 2022 the Company's Board of Directors approved an increase of $ 300 million to the Company's stock repurchase program. Repurchases under the share repurchase program are executed in the open market or negotiated transactions under trading plans established pursuant to Rule 10b5-1. The Company constructively retired the repurchased shares associated with these approved share repurchase programs, with all amounts paid in excess of par value reflected within Retained earnings in the Company’s consolidated balance sheets. The repurchase program may be suspended or discontinued at any time without notice.

Free historical financial statements for Medpace Holdings Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 21 quarters since 2018. Compare with MEDP stock chart to see long term trends.

Data imported from Medpace Holdings Inc SEC filings. Check original filings before making any investment decision.